Stocks discussed in the in-depth session of Jim Cramer’s Mad Money TV program, Monday December 11. Click on a stock ticker for more analysis:
More: Cramer's latest stock picks, including: Mad Money Recap, Lightening Round, Stop Trading and his Radio Show.
Although Cramer has often said that old media is dying, the oldest advertisements, billboards, are " coming back with a vengeance," because they are on the street where they cannot be avoided and are going digital. Daktronics is up 165%, but Cramer recommends buying it because the company "owns the market" in digital billboards, which he believes is the fastest growing form of advertising after the internet. The company also produces scoreboards for sports events. Cramer thinks Lamar is a better acquisition than CBS and Clear Channel, " because it is a pure play and is "going digital faster than any other company."
Related: Dealbook discusses the role Clear Channel's billboard business plays in attracting a buyer.
Safeway's Secret (NYSE:SWY)
Since many of the obvious holiday stocks are "played out" Cramer suggested a good oblique strategy for benefitting from the season by investing in Safeway which, in addition to running great stores, owns the $4-5 billion greeting card business, Blackhawk, whose products are sold by Barnes & Noble (NYSE:BKS), Apple's (NASDAQ:AAPL) iTunes, MasterCard (NYSE:MA), Nordstrom (NYSE:JWN), Home Depot (NYSE:HD) and Sears (NASDAQ:SHLD). Not many people are aware that Safeway owns Blackhawk, but when this is no longer a secret, the stock should rise, comments Cramer. In addition, Safeway's supermarkets are "financially sound enough to add a half-billion dollars to its buyback program last Friday and offer a dividend," and he would get into the stock before its analyst meeting on Tuesday.
CEO Interview: David Pyott of Allergan (NYSE:AGN)
David Pyott discussed the company's developing program for neuropathic pain and its rapid growth in the opthalmology sector. "The great position we have is that Allergan is the largest company in the world in the medical aesthetics space," he said, noting the popularity of breast implants, Botox and Juviderm among plastic surgery customers. Pyott also mentioned an upcoming trial between Juviderm and Medicis' Restylane to see which treatment customers like better and lasts longer. After the interview, Cramer commented that Thomas Weisel Partners' downgrade of Allergan was unfair, and that he would back up the truck as soon as the stock's price dips.
Related: Average Joe investor recommends Syneron for those who missed buying Allergan when it was cheap.
Get Cramer's Picks by email -- it's free and takes only a few seconds to sign up.
Seeking Alpha is not affiliated with CNBC, Jim Cramer or TheStreet.com